

Georg Goliasch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5372425/publications.pdf>

Version: 2024-02-01

80
papers

1,549
citations

393982

19
h-index

344852

36
g-index

80
all docs

80
docs citations

80
times ranked

2002
citing authors

#	ARTICLE	IF	CITATIONS
1	Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. <i>European Heart Journal</i> , 2018, 39, 39-46.	1.0	261
2	Natural History of Functional Tricuspid Regurgitation. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 389-397.	2.3	102
3	Familial-combined hyperlipidaemia in very young myocardial infarction survivors (<=40 years of age). <i>Tj ETQq1 1 0.784314 rgBT /Overlo</i>	1.0	92
4	A Unifying Concept for the Quantitative Assessment of Secondary Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2506-2517.	1.2	86
5	Evolution of outcome and complications in TAVR: a meta-analysis of observational and randomized studies. <i>Scientific Reports</i> , 2020, 10, 15568.	1.6	60
6	Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (≤40 years of age). <i>European Journal of Clinical Investigation</i> , 2012, 42, 631-636.	1.7	59
7	Premature myocardial infarction is strongly associated with increased levels of remnant cholesterol. <i>Journal of Clinical Lipidology</i> , 2015, 9, 801-806.e1.	0.6	45
8	Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction. <i>European Heart Journal</i> , 2020, 41, 2799-2810.	1.0	45
9	Evolution of secondary mitral regurgitation. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 622-629.	0.5	40
10	Duration of extracorporeal membrane oxygenation support and survival in cardiovascular surgery patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 2471-2476.	0.4	39
11	A machine learning algorithm supports ultrasound-naïve novices in the acquisition of diagnostic echocardiography loops and provides accurate estimation of LVEF. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 577-586.	0.7	37
12	Disproportionate Functional Mitral Regurgitation. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2088-2090.	2.3	32
13	Burden, treatment use, and outcome of secondary mitral regurgitation across the spectrum of heart failure: observational cohort study. <i>BMJ, The</i> , 2021, 373, n1421.	3.0	32
14	Blood urea nitrogen has additive value beyond estimated glomerular filtration rate for prediction of long-term mortality in patients with acute myocardial infarction. <i>European Journal of Internal Medicine</i> , 2019, 59, 84-90.	1.0	28
15	Principal Morphomic and Functional Components of Secondary Mitral Regurgitation. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2288-2300.	2.3	26
16	Increased resting heart rate and prognosis in treatment-naïve unselected cancer patients: results from a prospective observational study. <i>European Journal of Heart Failure</i> , 2020, 22, 1230-1238.	2.9	23
17	The inflammation-based modified Glasgow prognostic score is associated with survival in stable heart failure patients. <i>ESC Heart Failure</i> , 2020, 7, 654-662.	1.4	23
18	Immunomodulatory treatment for lymphocytic myocarditis—a systematic review and meta-analysis. <i>Heart Failure Reviews</i> , 2018, 23, 573-581.	1.7	22

#	ARTICLE	IF	CITATIONS
19	A Contemporary Definition of Periprocedural Myocardial Injury After Percutaneous Coronary Intervention of Chronic Total Occlusions. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1915-1923.	1.1	22
20	Syncope. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 225-232.	2.3	22
21	Impaired antioxidant HDL function is associated with premature myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2015, 45, 731-738.	1.7	21
22	Papillary Muscle Dyssynchrony-Mediated Functional Mitral Regurgitation. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1728-1737.	2.3	21
23	Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2021, 20, 34.	2.7	20
24	Natural Course of Nonsevere Secondary Tricuspid Regurgitation. <i>Journal of the American Society of Echocardiography</i> , 2021, 34, 13-19.	1.2	19
25	Lipid profile and long-term outcome in premature myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13008.	1.7	18
26	The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients. <i>Scientific Reports</i> , 2019, 9, 2554.	1.6	18
27	Myocardial Angiotensin Metabolism in End-Stage Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1731-1743.	1.2	18
28	Long-term outcome and risk assessment in premature acute myocardial infarction: A 10-year follow-up study. <i>International Journal of Cardiology</i> , 2017, 240, 37-42.	0.8	15
29	Quantitative Definition of Severe Functional Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2934-2935.	1.2	15
30	Adaptive development of concomitant secondary mitral and tricuspid regurgitation after transcatheter aortic valve replacement. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 1045-1053.	0.5	14
31	Impact of Right Ventricular Performance in Patients Undergoing Extracorporeal Membrane Oxygenation Following Cardiac Surgery. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	13
32	Increased concentrations of bioactive adrenomedullin subsequently to angiotensin receptor/neprilysin inhibitor treatment in chronic systolic heart failure. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 916-924.	1.1	13
33	Severe tricuspid regurgitation: prognostic role of right heart remodelling and pulmonary hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 246-254.	0.5	12
34	Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 725903.	1.1	12
35	Right ventricular function and outcome in patients undergoing transcatheter aortic valve replacement. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 1295-1303.	0.5	12
36	Malnutrition outweighs the effect of the obesity paradox. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1477-1486.	2.9	12

#	ARTICLE	IF	CITATIONS
37	Reverse Remodeling Following Valve Replacement in Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2022, 15, .	1.3	12
38	Refining Long-Term Prediction of Cardiovascular Risk in Diabetes â€” The VILDIA Score. <i>Scientific Reports</i> , 2017, 7, 4700.	1.6	11
39	Phenotyping progression of secondary mitral regurgitation in chronic systolic heart failure. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13159.	1.7	10
40	GDFâ€“15 in solid vs nonâ€“solid treatmentâ€“naÃ“ve malignancies. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13168.	1.7	10
41	Polyunsaturated fatty acids supplementation impairs antiâ€“oxidant highâ€“density lipoprotein function in heart failure. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12998.	1.7	9
42	Natural history of bivalvular functional regurgitation. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 565-573.	0.5	9
43	Sex-Related Differences in Low-Gradient, Lowâ€“Ejection Fraction Aortic Stenosis. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 203-205.	2.3	9
44	Heart Failure With Reduced Ejection Fraction Is Characterized by Systemic NEP Downregulation. <i>JACC Basic To Translational Science</i> , 2020, 5, 715-726.	1.9	9
45	Diagnostic assessment and procedural imaging for transcatheter edge-to-edge tricuspid valve repair: a step-by-step guide. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 8-10.	0.5	9
46	Access site complications of postcardiotomy extracorporeal life support. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1546-1558.e8.	0.4	9
47	Fate of patients weaned from post-cardiotomy extracorporeal life support. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 61, 1178-1185.	0.6	9
48	Guideline directed <i>medical</i> therapy and reduction of secondary mitral regurgitation. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 755-764.	0.5	9
49	Volume Status Impacts CMRâ€“Extracellular Volume Measurements and Outcome in AS Undergoing TAVR. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 516-518.	2.3	7
50	Fluid overload in patients undergoing TAVR: what we can learn from the nephrologists. <i>ESC Heart Failure</i> , 2021, 8, 1408-1416.	1.4	7
51	Global regurgitant volume: approaching the critical mass in valvular-driven heart failure. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 21, 168-174.	0.5	5
52	Systematic Evaluation of Systemic Right Ventricular Function. <i>Journal of Clinical Medicine</i> , 2020, 9, 107.	1.0	5
53	The Paradox of Secondary Mitral Regurgitation. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 740-741.	2.3	5
54	Impact of sex on the management and outcome of aortic stenosis patients: a female aortic valve stenosis paradox, and a call for personalized treatments?. <i>European Heart Journal</i> , 2021, 42, 2692-2694.	1.0	5

#	ARTICLE	IF	CITATIONS
55	Heart Failure with Preserved Ejection Fraction after Left-Sided Valve Surgery: Prevalent and Relevant. <i>European Journal of Heart Failure</i> , 2021, , .	2.9	5
56	Relevance of Neutrophil Neprilysin in Heart Failure. <i>Cells</i> , 2021, 10, 2922.	1.8	5
57	Cerebral Protection in TAVR—Can We Do Without? A Real-World All-Comer Intention-to-Treat Study—Impact on Stroke Rate, Length of Hospital Stay, and Twelve-Month Mortality. <i>Journal of Personalized Medicine</i> , 2022, 12, 320.	1.1	5
58	Aortic stenosis is an independent predictor for outcome in patients with in-hospital cardiac arrest. <i>Resuscitation</i> , 2019, 137, 156-160.	1.3	4
59	Secondary mitral regurgitation—Insights from microRNA assessment. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13381.	1.7	4
60	Transcatheter treatment by valve-in-valve and valve-in-ring implantation for prosthetic tricuspid valve dysfunction. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 780-785.	1.0	4
61	Reply. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1845-1847.	1.2	3
62	Left Main Coronary Artery Disease and Outcomes after Percutaneous Coronary Intervention for Chronic Total Occlusions. <i>Journal of Clinical Medicine</i> , 2020, 9, 938.	1.0	3
63	Neprilysin inhibition does not alter dynamic of proenkephalin—119—159 and pro-substance P in heart failure. <i>ESC Heart Failure</i> , 2021, 8, 2016-2024.	1.4	3
64	Prognostic Value of Echocardiographic Right Ventricular Function Parameters in the Presence of Severe Tricuspid Regurgitation. <i>Journal of Clinical Medicine</i> , 2021, 10, 2266.	1.0	3
65	A Real World 10-Year Experience With Vascular Closure Devices and Large-Bore Access in Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 791693.	1.1	3
66	Circulating dipeptidyl peptidase (cDPP3)—A marker for end-stage heart failure?. <i>Journal of Internal Medicine</i> , 2022, 291, 886-890.	2.7	2
67	Transcatheter Versus Surgical Valve Repair in Patients with Severe Mitral Regurgitation. <i>Journal of Personalized Medicine</i> , 2022, 12, 90.	1.1	2
68	An Integrated Imaging and Circulating Biomarker Approach for Secondary Tricuspid Regurgitation. <i>Journal of Personalized Medicine</i> , 2020, 10, 233.	1.1	1
69	Tricuspid regurgitation secondary to heart failure: more pieces to solve the puzzle. <i>European Journal of Heart Failure</i> , 2020, 22, 1814-1816.	2.9	1
70	Interventional treatment of tricuspid regurgitation. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 57-60.	1.0	1
71	Clinical Impact of Pre-Procedural Percutaneous Coronary Intervention in Low- and Intermediate-Risk Transcatheter Aortic Valve Replacement Recipients. <i>Journal of Personalized Medicine</i> , 2021, 11, 633.	1.1	1
72	Secondary tricuspid regurgitation: neglected no more!. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 166-167.	0.5	1

#	ARTICLE	IF	CITATIONS
73	The Authors Reply. JACC: Cardiovascular Imaging, 2019, 12, 1114.	2.3	0
74	The Authors Reply:. JACC: Cardiovascular Imaging, 2020, 13, 1458.	2.3	0
75	Current Insights Into Secondary Mitral Regurgitationâ€™Workup and Management. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.4	0
76	Simultaneous transcatheter mitral valve-in-mitral annular calcification and aortic valve-in-valve implantation: benefits of advanced multimodality imaging. European Heart Journal Cardiovascular Imaging, 2020, 21, 1433-1433.	0.5	0
77	The Authors Reply:. JACC: Cardiovascular Imaging, 2020, 13, 891.	2.3	0
78	Percutaneous bail-out in severe acute mitral regurgitation: when surgery is not an option. European Heart Journal - Case Reports, 2021, 5, ytab207.	0.3	0
79	Durable Reduction of Mitral Regurgitation After 2 Years. JACC: Cardiovascular Interventions, 2021, 14, 1549-1550.	1.1	0
80	Mitral regurgitation tips the scales in acute or worsening heart failure. European Journal of Heart Failure, 2021, 23, 1763-1764.	2.9	0